Earnings Call · Q4 FY2025·2026-02-26

Q4 25EPS +16.16%·Rev n/aQ3 25EPS +6.12%·Rev n/aQ2 25EPS +3.88%·Rev n/aQ1 25EPS +13.39%·Rev n/a⚠ consensus missing

Intellia Therapeutics, Inc. NTLA

Jason Fredette — Vice President of Investor Relations

John Leonard — Executive

Ed Dulac — Executive

+6.4%1d on move date+7.0% vs SPY3d+15.1%5d+3.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NTLA calls or request research access.

More NTLA calls Browse calls Request research access